Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Up 0.2% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) specializes in innovative treatments for conditions like eczema and eye diseases. The company recently announced robust quarterly results, mainly fueled by the success of its products Dupixent, Eylea HD, and Libtayo.

Why is Regeneron Pharmaceuticals Inc. going up?

REGN stock is up 0.2% on Aug 2, 2024 14:32

• Regeneron Pharmaceuticals outperformed expectations in the second quarter, reporting earnings per share of $11.56, marking a 13% increase from the previous year, and total revenues of $3.54 billion, a 12% rise.
• The strong demand for eczema and eye treatments like Dupixent and Eylea HD significantly contributed to the company's impressive performance, driving a positive movement in its stock value.
• The company's ability to meet market demand for its innovative pharmaceutical products, resulting in better-than-anticipated results and revenue growth, has bolstered investor confidence and elevated its stock price.
• Regeneron's success in delivering popular treatments and surpassing earnings projections has pushed its stock on an upward trajectory, outperforming its industry counterparts and fostering a favorable market outlook.

REGN Price Chart

REGN News

Regeneron Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

Regeneron Pharmaceuticals, Inc . (NASDAQ: REGN ) reported earnings per share of $11.56, which beat the Zacks Consensus Estimate of $10.57. The company recorded an EPS of $10.24 in the year-ago period. The upside in the bottom line can be attributed to higher revenues. Total revenues increased 12% year over year to $3.54 billion, fueled by higher Dupixent, Eylea HD and Libtayo sales. Revenues also beat the Zacks Consensus Estimate of $3.38 billion. Shares are trading up in response to the better-than-expected results. Regeneron''s shares have risen 22.8% year to date against the industry''s decline of 0.6%. Image Source: Zacks Investment Research Quarterly Highlights Eylea''s sales in the United States declined 18% year over year to $1.2 billion, primarily due to increased competition resulting in lower volumes and a reduced net selling price. Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG (OTC: BAYRY ). Regeneron records net product sales of Eylea in the United States and Bayer does the same outside the country.

https://www.benzinga.com/general/biotech/24/08/40103150/regeneron-tops-on-q2-earnings-eylea-hd-dupixent-fuel-sales

Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs - Regeneron Pharmaceuticals ( NASDAQ:REGN )

On Thursday, Regeneron Pharmaceuticals Inc REGN reported second-quarter adjusted EPS of $11.56, up 13% year-over-year, beating the consensus of $10.61. The company reported sales of $3.55 billion, up 12%, beating the consensus of $3.38 billion.

https://www.benzinga.com/general/biotech/24/08/40109548/regeneron-pharmaceuticals-q2-earnings-exceed-estimates-driven-by-its-top-selling-eczema-and-eye-d

Regeneron beats quarterly results on strong demand for eczema, eye treatments

https://www.investing.com/news/stock-market-news/regeneron-beats-quarterly-results-on-strong-demand-for-eczema-eye-treatments-3548908

https://www.investing.com/news/stock-market-news/regeneron-beats-quarterly-results-on-strong-demand-for-eczema-eye-treatments-3548908

The CHF is the strongest and the GBP isthe weakest as the North American session begins

As the North American session begins, the CHF is a stronger and the GBP is the weakest. The Bank of England (BOE) became the latest central bank to cut rates after reducing its bank rate by 25 basis points to 5.00% in a decision marked by close voting, with the vote split at 4-0-5. The four dissenting members, including Pill, Mann, Haskel, and Greene, preferred to maintain the current rate until there was stronger evidence that inflation pressures would not materialize. The decision was finely balanced, highlighting the BOE''s cautious approach in managing the rate cut. The BOE emphasized that while domestic inflationary persistence is expected to diminish over the next few years, there is a risk that second-round effects might sustain inflationary pressures in the medium term. The BOE aims to avoid cutting rates too quickly or by too much, ensuring the bank rate remains restrictive for a sufficiently long period to achieve a 2% inflation target sustainably. The degree of policy restrictiveness will be assessed at each meeting, reflecting uncertainty about the interaction between rate cuts and quantitative tightening.

https://www.forexlive.com/news/the-chf-is-the-strongest-and-the-gbp-isthe-weakest-as-the-north-american-session-begins-20240801/

ROUNDUP: Regeneron Pharma Q2 Results Top Estimates

WASHINGTON (dpa-AFX) - Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from …

https://www.finanznachrichten.de/nachrichten-2024-08/62883724-roundup-regeneron-pharma-q2-results-top-estimates-020.htm

Trending Today

Robinhood Inc. ($HOOD) Stock Forecast: Down 5.0% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Down 5.9% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.1% Today

GameStop Corp. ($GME) Stock Forecast: Up 6.2% Today

Solana ($SOL) Crypto Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Up 5.0% Today

Tyson Foods Inc. ($TSN) Stock Forecast: Down 3.2% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Down 5.7% Today

Aptos ($APT) Crypto Forecast: Up 7.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.2% Today

Regeneron Pharmaceuticals Inc. Price History

28.05.2023 - REGN Stock was down 11.4%

• REGN stock had a strong bearish movement today, falling 9%.
• The FDA rejected Regeneron's application for a higher-dose version of its eye disease therapy Eylea, leading to the downgrade of the stock by Canaccord Genuity.
• This news of FDA rejection likely caused the bearish movement in REGN stock.
• The overall positive market movement may have been driven by the rise in the US Consumer Confidence Index and anticipation of higher US GDP growth.

02.10.2023 - REGN Stock was up 5.5%

• The strong bullish movement in REGN stock today could be attributed to the positive news surrounding the company's high-dose Eylea treatment, which is off to a strong start.
• Despite a decrease in profit compared to the same period last year, Regeneron Pharmaceuticals managed to beat Street estimates, indicating resilience and positive market sentiment.
• The underperformance of Eylea sales may have initially caused concern, but the overall strong Q3 results, including higher revenue and earnings, have reassured investors and contributed to the bullish movement.
• The company's ability to beat quarterly profit estimates, particularly due to the strength of its eczema treatment, has likely further boosted investor confidence in Regeneron Pharmaceuticals.

20.02.2024 - REGN Stock was up 0.4%

• REGN stock experienced a strong bullish movement today.
• The bullish trend in REGN could be attributed to positive news surrounding the biotech industry, such as recent developments in a phase III study and the overall recovery of the biotech sector.
• The selling of over $5.5 million in stock by Regeneron's EVP research may have initially raised concerns but did not deter investors from driving the stock price higher.
• The bearish stance taken by some investors on REGN through options trading might have created short-term volatility, but the overall positive sentiment in the biotech market overshadowed this, leading to the bullish movement in REGN today.

03.05.2024 - REGN Stock was up 2.1%

• The bullish movement in REGN stock today can be attributed to the following factors:
• The FDA's decision to delay the verdict on Dupixent in COPD until September may have created anticipation and optimism among investors, as it indicates the regulatory body's thorough review and potential positive outcome.
• The recommendation for EU approval of Dupixent to treat COPD patients by CHMP could have boosted investor confidence in the drug's efficacy and market potential.
• The announcement of Neurocrine's CEO stepping down might have indirectly impacted REGN's stock positively, as it could signal upcoming strategic changes within the pharmaceutical industry that investors perceive as favorable.
• Overall, these developments surrounding Dupixent and regulatory approvals suggest a promising future for Regeneron Pharmaceuticals, driving the bullish market movement observed today.

27.10.2023 - REGN Stock was up 1.2%

• The bullish movement in REGN's stock today can be attributed to the following factors:
• 1. Positive trial results: The announcement of Sanofi's plans to seek U.S. approval for wider use of Dupixent in treating chronic obstructive pulmonary disease (COPD) after a successful second trial has boosted investor confidence. This potential expansion of Dupixent's applications could significantly contribute to REGN's growth prospects.
• 2. Increasing institutional investment: The Manufacturers Life Insurance Company has been steadily increasing its holdings in REGN, indicating a growing interest from institutional investors. This additional investment further reinforces the positive sentiment surrounding the company's future prospects.
• 3. Strong pipeline progress: REGN's stock has also been supported by the impressive progress of its pipeline, with the recent approval of Eylea HD and the continued momentum of Dupixent. These developments demonstrate the company's commitment to innovation and its ability to bring successful drugs to market.
• Overall, the bullish movement in REGN's stock today can be attributed to the positive trial results for Dupixent in treating COPD, increasing institutional investment, and the company's strong pipeline progress.

27.05.2023 - REGN Stock was down 9.0%

• REGN had a strong bearish movement today, possibly due to the FDA issuing a Complete Response Letter for Aflibercept 8 mg Biologics License Application, which was solely due to an ongoing review of inspection findings at a third-party filler.
• The market might have reacted negatively to the news, as it could delay the approval process for the drug.
• However, the two-year results for Aflibercept 8 mg from the pivotal PHOTON trial demonstrated durable vision gains at extended dosing intervals in diabetic macular edema, which could be a positive sign for the drug's future prospects.

27.10.2023 - REGN Stock was up 2.0%

• REGN's bullish movement today can be attributed to the news that Sanofi and Regeneron are set to file for FDA approval of Dupixent for the treatment of chronic obstructive pulmonary disease (COPD). This potential expansion of Dupixent's use could significantly boost REGN's growth prospects.
• The positive results from a second large trial of Dupixent in COPD, which showed a 34% reduction in exacerbations of the disease, further supported the potential approval and wider use of the drug.
• The increase in REGN's stock could also be influenced by the growing interest from institutional investors, such as The Manufacturers Life Insurance Company, which acquired additional shares of the company during the 2nd quarter.
• Overall, REGN's bullish movement today can be attributed to the positive developments surrounding Dupixent and its potential expansion into treating COPD, as well as the growing confidence from institutional investors.

25.03.2024 - REGN Stock was down 3.4%

• Despite an increase in the price target for Regeneron stock, the market may have reacted negatively to the recent pullback, leading to the bearish movement.
• A change in the rating from "strong-buy" to "buy" could have influenced investor sentiment and contributed to the downward pressure on the stock.
• The focus on genetic medicine research advancements and promising early results in gene therapy programs at a recent conference may have not been enough to offset the overall market sentiment.
• An industry comparison analysis might have highlighted challenges or weaknesses in Regeneron Pharmaceuticals compared to its competitors, impacting the stock's performance negatively.

03.07.2023 - REGN Stock was up 6.1%

• The bullish movement in REGN's stock today can be attributed to the following factors:
• 1. Positive earnings expectations: Analysts estimate that REGN will report an earnings per share (EPS) of $9.92, and investors are hopeful that the company will exceed this estimate. Positive earnings results often lead to increased investor confidence and can drive stock prices higher.
• 2. Market delay for a competitor: REGN's shares declined as the company faced a market delay for its drug Eylea, allowing a competitor, Roche's Vabysmo, to gain ground. This setback for the competitor could have boosted investor sentiment towards REGN, leading to a bullish movement in the stock.
• 3. Long-term outperformance: REGN has outperformed the market over the past 20 years, with an average annual return of 22.59%. This track record of strong performance may have attracted investors, contributing to the bullish movement in the stock.
• 4. Overall positive sentiment in the biotech sector: The biotech sector is forecasted to grow at a compound annual growth rate of 14%, presenting attractive opportunities for investors. With the global biotech industry continuing to expand, investors may be drawn to REGN as a promising player in the sector.
• Overall, positive earnings expectations, a competitor's market delay, REGN's long-term outperformance, and positive sentiment in the biotech sector likely contributed to the bullish movement in REGN's stock today.

08.08.2023 - REGN Stock was up 1.7%

• Today, REGN experienced a strong bullish movement. Here's what might have caused the market movement:
• Positive sentiment from the Wells Fargo Healthcare Conference, where Regeneron's management presented, could have boosted investor confidence in the company's future prospects.
• The clinical trial supply agreement with OncoNano for the use of Libtayo in the ONM-501 study indicates potential advancements in Regeneron's pipeline, which could have sparked investor optimism.
• The article highlighting Regeneron's outperformance in the market over the past 20 years and its current market capitalization may have attracted investors looking for long-term growth opportunities.
• While not directly related to Regeneron, the mention of the allergic conjunctivitis market's expected growth could have indirectly influenced investor sentiment, considering Regeneron's presence in the ophthalmology sector.
• Overall, a combination of positive news and market sentiment likely contributed to REGN's bullish movement today.

01.07.2024 - REGN Stock was up 3.6%

• REGN stock showed significant upward momentum recently.
• This positive trend is due to Regeneron exceeding expectations in its latest financial results, fueled by strong demand for its eczema and eye treatments.
• The company posted impressive Q2 2024 financial and operational figures, including a notable rise in net income and revenue, alongside the approval of Dupixent for COPD in the EU.
• Investor confidence in REGN was further boosted by the substantial increase in EYLEA HD sales and the progress of over 35 candidates in the company's product pipeline.

02.07.2024 - REGN Stock was up 0.2%

• Regeneron Pharmaceuticals outperformed expectations in the second quarter, reporting earnings per share of $11.56, marking a 13% increase from the previous year, and total revenues of $3.54 billion, a 12% rise.
• The strong demand for eczema and eye treatments like Dupixent and Eylea HD significantly contributed to the company's impressive performance, driving a positive movement in its stock value.
• The company's ability to meet market demand for its innovative pharmaceutical products, resulting in better-than-anticipated results and revenue growth, has bolstered investor confidence and elevated its stock price.
• Regeneron's success in delivering popular treatments and surpassing earnings projections has pushed its stock on an upward trajectory, outperforming its industry counterparts and fostering a favorable market outlook.